Contra-indicated in patients with advanced malignant hepatic tumors.
- TRADE NAME: Vidaza (Celgene)
- INDICATIONS: Myelodysplastic syndromes, refractory anemia
- SYNONYM: Azacytidine
- CLASS: Antimetabolite, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Cytosine analog
- HALF-LIFE: 40–56 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCG Vaccine, Denosumab, Echinacea, Leflunomide, Natalizumab, Pimecrolimus, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Page last updated 03/08/2025
